Literature DB >> 25482074

Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation.

Mohan S Maddur1,2,3,4, Jamma Trinath1,5, Magalie Rabin1,2,3,6, Francis Bolgert7, Moneger Guy7, Jean-Michel Vallat6, Laurent Magy6, Kithiganahalli N Balaji5, Srini V Kaveri1,2,3,4,8, Jagadeesh Bayry1,2,3,4,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25482074      PMCID： PMC4579644          DOI： 10.1038/cmi.2014.117

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  10 in total

1.  Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease.

Authors:  Jagadeesh Bayry; Luc Mouthon; Srini V Kaveri
Journal:  J Rheumatol       Date:  2012-02       Impact factor: 4.666

2.  High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis.

Authors:  Naomi Tsurikisawa; Hiroshi Saito; Chiyako Oshikata; Takahiro Tsuburai; Kazuo Akiyama
Journal:  J Rheumatol       Date:  2012-04-01       Impact factor: 4.666

3.  Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function.

Authors:  Aharon Kessel; Hana Ammuri; Regina Peri; Elsa R Pavlotzky; Miri Blank; Yehuda Shoenfeld; Elias Toubi
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

Review 4.  What is the contents of the magic draft IVIg?

Authors:  Jean-François Seite; Yehuda Shoenfeld; Pierre Youinou; Sophie Hillion
Journal:  Autoimmun Rev       Date:  2008-05-02       Impact factor: 9.754

Review 5.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

Review 6.  Regulation of immune responses by prostaglandin E2.

Authors:  Pawel Kalinski
Journal:  J Immunol       Date:  2012-01-01       Impact factor: 5.422

Review 7.  Intravenous immunoglobulin therapy in rheumatic diseases.

Authors:  Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

8.  Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells.

Authors:  Amir H Massoud; Madelaine Yona; Di Xue; Fazila Chouiali; Haydar Alturaihi; Aidan Ablona; Walid Mourad; Ciriaco A Piccirillo; Bruce D Mazer
Journal:  J Allergy Clin Immunol       Date:  2013-11-08       Impact factor: 10.793

9.  Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells.

Authors:  Jamma Trinath; Pushpa Hegde; Meenu Sharma; Mohan S Maddur; Magalie Rabin; Jean-Michel Vallat; Laurent Magy; Kithiganahalli N Balaji; Srini V Kaveri; Jagadeesh Bayry
Journal:  Blood       Date:  2013-07-11       Impact factor: 22.113

10.  Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists.

Authors:  Alice E Wiedeman; Deanna M Santer; Wei Yan; Sylvia Miescher; Fabian Käsermann; Keith B Elkon
Journal:  Arthritis Rheum       Date:  2013-10
  10 in total
  19 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1.

Authors:  Lora Hamuro; Giridhar S Tirucherai; Sean M Crawford; Akbar Nayeem; Renuka C Pillutla; Binodh S DeSilva; Tarek A Leil; Craig J Thalhauser
Journal:  AAPS J       Date:  2019-07-24       Impact factor: 4.009

Review 3.  Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis.

Authors:  Mohan S Maddur; Sébastien Lacroix-Desmazes; Jordan D Dimitrov; Michel D Kazatchkine; Jagadeesh Bayry; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 4.  Manipulating regulatory T cells: a promising strategy to treat autoimmunity.

Authors:  Dunfang Zhang; Eric Tu; Shimpei Kasagi; Peter Zanvit; Qianming Chen; WanJun Chen
Journal:  Immunotherapy       Date:  2015-11-16       Impact factor: 4.196

5.  Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia.

Authors:  Zhenhua Zhao; Lei Yang; Guohua Yang; Yun Zhuang; Xifeng Qian; Xin Zhou; Dajiang Xiao; Yunfeng Shen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

Review 6.  Novel pathomechanisms in inflammatory neuropathies.

Authors:  David Schafflick; Bernd C Kieseier; Heinz Wiendl; Gerd Meyer Zu Horste
Journal:  J Neuroinflammation       Date:  2017-11-28       Impact factor: 8.322

7.  A single center experience of intravenous immunoglobulin treatment in Covid-19.

Authors:  Ahmet Omma; Abdulsamet Erden; Berkan Armağan; Serdar Can Güven; Özlem Karakaş; Enes Seyda Şahiner; Deniz Erdem; Seval İzdeş; İhsan Ateş; Orhan Küçükşahin
Journal:  Int Immunopharmacol       Date:  2021-06-14       Impact factor: 5.714

Review 8.  Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.

Authors:  Ying Wang; Shuang Sun; Jie Zhu; Li Cui; Hong-Liang Zhang
Journal:  Mediators Inflamm       Date:  2015-09-16       Impact factor: 4.711

9.  Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin.

Authors:  Caroline Galeotti; Pushpa Hegde; Mrinmoy Das; Emmanuel Stephen-Victor; Fernando Canale; Marcos Muñoz; Varun K Sharma; Jordan D Dimitrov; Srini V Kaveri; Jagadeesh Bayry
Journal:  Sci Rep       Date:  2016-01-22       Impact factor: 4.379

10.  Plasma Prostaglandin E2 Levels Correlated with the Prevention of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions Formation via CD40L in Kawasaki Disease.

Authors:  Ho-Chang Kuo; Chih-Lu Wang; Kuender D Yang; Mao-Hung Lo; Kai-Sheng Hsieh; Sung-Chou Li; Ying-Hsien Huang
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.